| MeSH term | MeSH ID | Detail |
|---|---|---|
| Arteriosclerosis Obliterans | D001162 | 8 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Arthritis, Juvenile | D001171 | 8 associated lipids |
| Arthus Reaction | D001183 | 8 associated lipids |
| Ascites | D001201 | 25 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Asthma | D001249 | 52 associated lipids |
| Atrial Fibrillation | D001281 | 16 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
Thromboxane b2
Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
Cross Reference
Introduction
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Thromboxane b2?
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
PubChem Associated disorders and diseases
What pathways are associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Thromboxane b2?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Thromboxane b2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Thromboxane b2?
There are no associated biomedical information in the current reference collection.
What genes are associated with Thromboxane b2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Thromboxane b2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Thromboxane b2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wang JP et al. | Antiplatelet effect of hsien-ho-t'sao (Agrimonia pilosa). | 1985 | Am. J. Chin. Med. | pmid:3927704 |
| Yan LG et al. | Injectable caltrop fruit saponin protects against ischemia-reperfusion injury in rat brain. | 2011 | Am. J. Chin. Med. | pmid:21476209 |
| Takase B et al. | Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction. | 1994 | Am. J. Cardiol. | pmid:8198031 |
| Fulton DR et al. | Effects of current therapy of Kawasaki disease on eicosanoid metabolism. | 1988 | Am. J. Cardiol. | pmid:2454025 |
| Catella-Lawson F et al. | Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. | 2001 | Am. J. Cardiol. | pmid:11472700 |
| Hanet C et al. | Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty. | 1987 | Am. J. Cardiol. | pmid:2953226 |
| Faraday N et al. | Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. | 2006 | Am. J. Cardiol. | pmid:16950183 |
| Yasu T et al. | Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. | 1993 | Am. J. Cardiol. | pmid:8480641 |
| Willerson JT et al. | Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes. | 1990 | Am. J. Cardiol. | pmid:2146868 |
| McDaniel HG et al. | Platelet function abnormalities in response to arachidonic acid in the acute phase of myocardial infarction. | 1983 | Am. J. Cardiol. | pmid:6416046 |
| De Caterina R et al. | Inhibition of platelet function by injectable isosorbide dinitrate. | 1984 | Am. J. Cardiol. | pmid:6428211 |
| Eldar M et al. | Bradykinin level in the great cardiac vein during balloon angioplasty of the left anterior descending coronary artery. | 1992 | Am. J. Cardiol. | pmid:1466338 |
| Dabaghi SF et al. | Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. | 1994 | Am. J. Cardiol. | pmid:7942533 |
| Graziani F et al. | Thromboxane production in morbidly obese subjects. | 2011 | Am. J. Cardiol. | pmid:21439532 |
| Théroux P et al. | Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris. | 1990 | Am. J. Cardiol. | pmid:2109927 |
| Feldman M and Cryer B | Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. | 1999 | Am. J. Cardiol. | pmid:10468077 |
| Willerson JT et al. | Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. | 1984 | Am. J. Cardiol. | pmid:6391133 |
| Hirsh PD et al. | Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. | 1983 | Am. J. Cardiol. | pmid:6829431 |
| Walinsky P et al. | Beneficial effects of ibuprofen in pacing-induced myocardial ischemia. | 1983 | Am. J. Cardiol. | pmid:6829434 |
| Milani M et al. | Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. | 1995 | Am. J. Cardiol. | pmid:7604798 |
| Roy L et al. | Increased plasma concentrations of prostacyclin metabolite 6-keto-PGF1 alpha in essential hypertension. Influence of therapy with labetalol. | 1983 | Am. J. Cardiol. | pmid:6823861 |
| Shen H et al. | Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). | 2009 | Am. J. Cardiol. | pmid:19660620 |
| Lam JY et al. | Platelet aggregation, coronary artery disease progression and future coronary events. | 1994 | Am. J. Cardiol. | pmid:8109546 |
| Timmermans C et al. | Ridogrel in the setting of percutaneous transluminal coronary angioplasty. | 1991 | Am. J. Cardiol. | pmid:1872272 |
| Mason PJ et al. | Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. | 2005 | Am. J. Cardiol. | pmid:16275179 |
| Rehr RB et al. | Mechanism of nitroglycerin-induced coronary dilatation: lack of relation to intracoronary thromboxane concentrations. | 1984 | Am. J. Cardiol. | pmid:6437206 |
| Montalescot G et al. | Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. | 1990 | Am. Heart J. | pmid:2248190 |
| Hirsh PD et al. | Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. | 1982 | Am. Heart J. | pmid:7102506 |
| Smith EF and Lefer AM | Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion:efficacy of the nonsteroidal anti-inflammatory agent, naproxen. | 1981 | Am. Heart J. | pmid:7211667 |
| Nakashima Y et al. | Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. | 1990 | Am. Heart J. | pmid:2353613 |
| Ikonomidis I et al. | Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. | 2005 | Am. Heart J. | pmid:15894964 |
| Kishi Y et al. | Inhibition of platelet aggregation by prostacyclin is attenuated after exercise in patients with angina pectoris. | 1992 | Am. Heart J. | pmid:1736562 |
| Tomoda H | Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). | 1986 | Am. Heart J. | pmid:3532743 |
| Nitz RE and Martorana PA | The activity of molsidomine in experimental models of ischemic cardiac disease. | 1985 | Am. Heart J. | pmid:3919549 |
| Buchanan MR et al. | Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. | 1987 | Am. Heart J. | pmid:2953219 |
| Walinsky P et al. | Thromboxane A2 in acute myocardial infarction. | 1984 | Am. Heart J. | pmid:6485997 |
| Rubenstein MD et al. | Platelet activation in clinical coronary artery disease and spasm. | 1981 | Am. Heart J. | pmid:6455912 |
| De Caterina R et al. | Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. | 1990 | Am. Heart J. | pmid:2321506 |
| Buerke M et al. | Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. | 1995 | Am. Heart J. | pmid:7661062 |
| De Servi S et al. | Coronary vasoconstrictor response to cold pressor test in variant angina: lack of relation to intracoronary thromboxane concentrations. | 1987 | Am. Heart J. | pmid:3630891 |
| Cotter G et al. | Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? | 2004 | Am. Heart J. | pmid:14760328 |
| Mehta J and Mehta P | Prostacyclin and thromboxane A2 production by human cardiac atrial tissues. | 1985 | Am. Heart J. | pmid:3880988 |
| Friedrich T et al. | Follow-up of prostaglandin plasma levels after acute myocardial infarction. | 1985 | Am. Heart J. | pmid:3880994 |
| O'Connor KM et al. | The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. | 1989 | Am. Heart J. | pmid:2929400 |
| Zhu BQ and Parmley WW | Modification of experimental and clinical atherosclerosis by dietary fish oil. | 1990 | Am. Heart J. | pmid:2105047 |
| O'Connor KM et al. | Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. | 1986 | Am. Heart J. | pmid:3953390 |
| Austin JC et al. | Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. | 1988 | Am. Heart J. | pmid:3344655 |
| Arora RR et al. | Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. | 1993 | Am. Heart J. | pmid:8381256 |
| Jouve R et al. | Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. | 1984 | Am. Heart J. | pmid:6581715 |
| Rebuzzi AG et al. | Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. | 1992 | Am. Heart J. | pmid:1539506 |